Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6

被引:58
作者
Denton, TT [1 ]
Zhang, XD [1 ]
Cashman, JR [1 ]
机构
[1] Human Biomol Res Inst, San Diego, CA 92121 USA
关键词
cytochrome P-450 2A6; S-(-)-nicotine; beta-nicotyrine; S-(-)-anatabine; S-(-)-anabasine; 2,3 '-bipyridyl;
D O I
10.1016/j.bcp.2003.10.022
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
S-(-)-Nicotine and 13 of the most prevalent nicotine-related alkaloids and metabolites (i.e., S-(-)-nornicotine, myosmine, beta-nicotyrine, S-cotinine, S-norcotinine, S-(-)-nicotine N-1'-oxide, S-(-)-mcotme Delta (1'-5') -iminium ion, S-(-)-anabasine, S-(-)-N-methylanabasine, anabaseine, S-(-)-anatabine, nicotelline, and 2,3'-bipyridyl) were evaluated as inhibitors of human cDNA-expressed cytochrome P-450 2A6 (CYP2A6) mediated coumarin 7-hydroxylation. Tobacco alkaloids myosmine, S-(-)-nornicotine, S-cotinine, S-norcotinine, S-(-)-nicotine N-1'-oxide, S-(-)-nicotine Delta(1'-5') iminium ion, S-(-)-N-methylanabasine, anabaseine, and nicotelline had K-i values for inhibition of coumarin 7-hydroxylation ranging from 20 muM to more than 300 muM whereas nicotine and S-(-)-anatabine were much more potent (i.e. 4.4 and 3.8 muM, respectively). The tobacco alkaloids 2,3'-bipyridyl (7.7 muM) and S-(-)-anabasine (5.4 muM), were somewhat less potent compared with S-(-)-nicotine or S-(-)-anatabine in inhibition of human CYP2A6. P-Nicotyrine, in which the N-methylpyrrolidino moiety of nicotine was replaced by the aromatic N-methylpyrrole ring, was shown to inhibit human CYP2A6 with much greater potency (K-i = 0.37 muM) compared with S-(-)-nicotine. Among the compounds examined, only nicotine and beta-nicotyrine were mechanism-based inhibitors of human CYP2A6. The potency of the mechanism-based CYP2A6 inhibitors suggests that, for smokers, modulation of CYP2A6 may be greater than that predicted on the basis of serum concentration of these alkaloids. Our results indicate that the prominent nicotine-related alkaloid P-nicotyrine present after smoking potently inhibits human CYP2A6. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:751 / 756
页数:6
相关论文
共 31 条
  • [11] Tobacco use, cancer causation and public health impact
    Kuper, H
    Adami, HO
    Boffetta, P
    [J]. JOURNAL OF INTERNAL MEDICINE, 2002, 251 (06) : 455 - 466
  • [12] Tobacco use and cancer causation: association by tumour type
    Kuper, H
    Boffetta, P
    Adami, HO
    [J]. JOURNAL OF INTERNAL MEDICINE, 2002, 252 (03) : 206 - 224
  • [13] Studies on the pyrrolinone metabolites derived from the tobacco alkaloid 1-methyl-2-(3-pyridinyl)pyrrole (β-nicotyrine)
    Liu, X
    Zang, LY
    Van der Schyf, CJ
    Igarashi, K
    Castagnoli, K
    Castagnoli, N
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 1999, 12 (06) : 508 - 512
  • [14] Studies on the in vivo biotransformation of the tobacco alkaloid β-nicotyrine
    Liu, X
    Castagnoli, K
    Van der Schyf, CJ
    Castagnoli, N
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2000, 13 (05) : 336 - 341
  • [15] Inhibition of human liver microsomal (S)-nicotine oxidation by (-)-menthol and analogues
    MacDougall, JM
    Fandrick, K
    Zhang, XD
    Serafin, SV
    Cashman, JR
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2003, 16 (08) : 988 - 993
  • [16] A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic Vivid® P450 substrate
    Marks, BD
    Smith, RW
    Braun, HA
    Goossens, TA
    Christenson, M
    Ozers, MS
    Lebakken, CS
    Trubetskoy, OV
    [J]. ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2002, 1 (01) : 73 - 81
  • [17] Messina ES, 1997, J PHARMACOL EXP THER, V282, P1608
  • [18] Characterization of multiple products of cytochrome P450 2A6-catalyzed cotinine metabolism
    Murphy, SE
    Johnson, LM
    Pullo, DA
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 1999, 12 (07) : 639 - 645
  • [19] Nakajima M, 1996, J PHARMACOL EXP THER, V277, P1010
  • [20] Nicotine metabolism and intake in black and white smokers
    Pérez-Stable, EJ
    Herrera, B
    Jacob, P
    Benowitz, NL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (02): : 152 - 156